Vitality Watch

Dossier clinicaltrials trial early 10-aug-2026
Small or early-phase human trial or pilot study

Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers

Key claim: A 12-week randomized, placebo-controlled trial will test whether daily Urolithin A (500 mg), fisetin (500 mg), or their combination (300 mg UA + 200 mg fisetin) improves sleep quality and aging biomarkers in middle-aged and older adults.

Abstract

The goal of this clinical trial is to evaluate the effects of Urolithin A (UA) and Fisetin on improving sleep and aging biomarkers in middle-aged and older adults. The main questions it aims to answer are:

Can UA and Fisetin improve sleep quality in middle-aged and older adults? Do these substances have a positive effect on aging biomarkers, such as inflammation, oxidative stress, and aging-related proteins? Researchers will compare four groups: Placebo group (a look-alike substance that contains no drug), 500 mg UA group, 500 mg Fisetin group and 300 mg UA + 200 mg Fisetin group.

Participants will:

Take the assigned capsules daily after breakfast for 12 weeks. Attend three clinic visits (baseline [Week 0], mid-intervention [Week 4], and post-intervention [Week 12]) including blood tests, sleep quality assessments (PSQI scale, actigraphy, polysomnography), and analysis of aging biomarkers (DNA methylation, inflammatory cytokines, etc.). Keep a sleep diary, complete a dietary survey, assess mental health, and measure frailty indicators. Provide stool and urine samples at baseline and post-intervention for gut microbiome and metabolite analysis. This trial aims to provide scientific evidence for the development of new nutritional intervention strategies to improve the healthy aging.

Why this matters

This is one of the few registered RCTs that will co-measure methylation clocks, inflammation, and microbiome age against a mitophagy activator plus a senolytic flavonoid, so its readout will inform how sensitive multi-modal aging biomarkers are to short-course nutraceutical combinations. Protocols like this are the pipeline from which independent validation (or lack of it) for these clocks eventually emerges. As always, any clock movement observed here will be a statistical shift, not proof of de-aging.

Source

Link

Briefing card

Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers
Stage: trial early · clinicaltrials · 10-aug-2026

If you are taking urolithin A or fisetin for sleep or general anti-aging, this trial is the first RCT designed to test that pairing but has not yet reported results.

A 12-week randomized, placebo-controlled trial will test whether daily Urolithin A (500 mg), fisetin (500 mg), or their combination (300 mg UA + 200 mg fisetin) improves sleep quality and aging biomarkers in middle-aged and older adults.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT06990256

build build 880 · 2bcef25 · 2026-11-18